Synergistic effect of HPMA copolymer-bound doxorubicin and dexamethasone in vivo on mouse lymphomas

Journal of Bioactive and Compatible Polymers

Volumn 26, Issue 3, 2011, Pages 270-286

  Kostková, Hana ^a   Etrych, Tomás̊ ^a   S̊íhová, Blanka ^b   Ulbrich, Karel ^a  

^a INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

^b INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

B cell lymphoma; combination therapy; dexamethasone; doxorubicin; drug delivery; HPMA copolymer; T cell lymphoma

Indexed keywords

B-CELL LYMPHOMA; COMBINATION THERAPY; DEXAMETHASONES; DOXORUBICIN; HPMA COPOLYMER; T-CELL LYMPHOMA;

BEARINGS (STRUCTURAL); CELLS; COPOLYMERIZATION; DISEASES; DRUG DELIVERY; ONCOLOGY;

COPOLYMERS;

DEXAMETHASONE; DOXORUBICIN; N (2 HYDROXYPROPYL)METHACRYLAMIDE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BLOOD PH; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG HYDROLYSIS; DRUG POTENTIATION; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; T CELL LYMPHOMA;

MUS;

EID: 79957634222     PISSN: 08839115     EISSN: 15308030     Source Type: Journal    
DOI: 10.1177/0883911511406326     Document Type: Article

References (32)

1. Peterson CM, Lu JM, Sun Y., et al. Combination chemotherapy and photodynamic therapy with N-(2- hydroxypropyl)methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res 1996 ; 56 (17). 3980-3985. (Pubitemid 26284748)
2. Vicent MJ, Greco F., Nicholson RI, et al. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew Chem Int Ed Engl 2005 ; 44 (26). 4061-4066. (Pubitemid 40886448)
3. Alexanian R., Dimopoulos MA, Delasalle K., et al. Primary dexamethasone treatment of multiple myeloma. Blood 1992 ; 80 (4). 887-890.
4. Hussein MA, Wood L., Hsi E., et al. A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 2002 ; 95 (10). 2160-2168. (Pubitemid 35253378)
5. Oakervee HE, Popat R., Curry N., et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005 ; 129 (6). 755-762. (Pubitemid 40904525)
6. Tosi P., Zamagni E., Cellini C., et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 2004 ; 73 (2). 98-103. (Pubitemid 38980109)
7. Garcia-Sanz R., Gonzalez-Lopez TJ, Vazquez L., et al. The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma. Eur J Haematol 2010 ; 84 (3). 266-270.
8. Gozzetti A., Fabbri A., Oliva S., et al. Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2010 ; 10 (1). 68-72.
9. Hussein MA Modifications to therapy for multiple myeloma: pegylated liposomal doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide. Oncologist 2003 ; 8 (Suppl. 3). 39-45.
10. Lokhorst HM, Van Der Holt B., Zweegman S., et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010 ; 115 (6). 1113-1120.
11. Offidani M., Leoni P., Corvatta L., et al. ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma. Eur J Haematol 2010 ; 84 (6). 474-483.
12. Tsukune Y., Isobe Y., Yasuda H., et al. Activity and safety of combination chemotherapy with methotrexate, ifosfamide, L-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study. Eur J Haematol 2010 ; 84 (4). 310-315.
13. Wang H., Li M., Rinehart JJ and Zhang R. Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. Cancer Chemother Pharmacol 2004 ; 53 (6). 459-467. (Pubitemid 38680242)
14. Wang H., Li M., Rinehart JJ and Zhang R. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res 2004 ; 10 (5). 1633-1644. (Pubitemid 38435553)
15. Wang H., Wang Y., Rayburn ER, et al. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int J Oncol 2007 ; 30 (4). 947-953.
16. Duncan R. and Vicent MJ Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv Drug Deliv Rev 2010 ; 62 (2). 272-282.
17. Ulbrich K. and Subr V. Structural and chemical aspects of HPMA copolymers as drug carriers. Adv Drug Deliv Rev 2010 ; 62 (2). 150-166.
18. Kopeĉek J. and Kopeĉková P. HPMA copolymers: Origins, early developments, present, and future. Adv Drug Deliv Rev 2010 ; 62 (2). 122-149.
19. Kopecek J., Kopecková P., Minko T. and Lu ZR HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 2000 ; 50 (1). 61-81. (Pubitemid 30326689)
20. S̊íhová B. and Kováa M. Immunogenicity and immunomodulatory properties of HPMA-based polymers. Adv Drug Deliv Rev 2010 ; 62 (2). 184-191.
21. Krakoviĉová H., Etrych T. and Ulbrich K. HPMA-based polymer conjugates with drug combination. Eur J Pharm Sci 2009 ; 37: 405-412.
22. Leinweber FJ Possible physiological roles of carboxylic ester hydrolases. Drug Metab Rev 1987 ; 18 (4). 379-439.
23. Li B., Sedlacek M., Manoharan I., et al. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 2005 ; 70 (11). 1673-1684. (Pubitemid 41540360)
24. Ulbrich K., Åubr V., Strohalm J., et al. Polymeric drugs based on conjugates of synthetic and natural macromolecules I. Synthesis and physico-chemical characterisation. J Control Release 2000 ; 64: 63-79. (Pubitemid 30035308)
25. Etrych T., Mrkvan T., Chytil P., et al. N-(2-hydroxypropyl) methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin. I. New synthesis, physicochemical characterization and preliminary biological evaluation. J Appl Polym Sci 2008 ; 109 (5). 3050-3061.
26. S̊íhová B., Etrych T., Pechar M., et al. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes. J Control Release 2001 ; 74: 225-232. (Pubitemid 32727624)
27. Mrkvan T., Åírová M., Etrych T., et al. Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity. J Control Release 2005 ; 110: 119-129. (Pubitemid 41713936)
28. Etrych T., Jelínková M., S̊íhová B. and Ulbrich K. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J Control Release 2001 ; 73: 89-102. (Pubitemid 32406104)
29. Etrych T., Chytil P., Jelínková M., et al. Synthesis of HPMA copolymers containing doxorubicin bound via a hydrazone linkage: effect of spacer on drug release and in vitro cytotoxicity. Macromol Biosci 2002 ; 2 (1). 43-52. (Pubitemid 44790994)
30. Etrych T., Mrkvan T., Chytil P., et al. Polymer prodrugs based on HPMA conjugates with pH-controlled activation of doxorubicin: I. Synthesis, physicochemical characterisation and preliminary biological evaluation. Macromol Biosci 2009 ; 37 (3-4). 405-412.
31. Etrych T., Åírová M., Starovoytova L., et al. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release. Mol Pharm 2010 ; 7 (4). 1015-1026.
32. Sirova M., Strohalm J., Subr V., et al. Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice. Cancer Immunol Immunother 2007 ; 56 (1). 35-47. (Pubitemid 44812445)